High-Concentration EPA: A New Health Option for People in a Sub-health and the Middle-aged and Elderly People
Sub-health conditions are widespread among young and middle-aged people, and cardiovascular health and cognitive maintenance are directly related to the quality of life of the elderly.
Chronic inflammation and metabolic disorders are the core pathological basis of sub-health, and the sub-health state is often closely related to metabolic syndrome-related manifestations such as abdominal obesity and dyslipidemia. Research has confirmed that high concentration EPA demonstrates dual effects of anti-inflammation and metabolic regulation in sub-health intervention: High concentration EPA can reduce triglycerides by 33.1% without increasing low-density lipoprotein cholesterol (LDL-C) [1]. It also has a clear improvement in lipid disorders and chronic inflammatory states in patients with metabolic syndrome, and may even help maintain body composition and bone health [2].
For middle-aged and elderly people, research has confirmed that daily supplementation of 1.8 g of EPA can reduce the risk of major coronary events by 19%[3]; The REDUCE-IT study further demonstrated that high-purity EPA (4 g/ day) reduced the risk of major adverse cardiovascular events by an additional 25% on the basis of statin treatment [4].
The third-generation fish oil technology can achieve an EPA concentration of over 90% through supercritical chromatography separation technology. For instance, the EPA purity of MegaGold EPA1000 reaches 98%. When choosing fish oil, priority should be given to high-purity preparations that have been clinically verified to ensure bioavailability and intervention effects.
In conclusion, high concentration EPA, with multiple pieces of evidence including cardiovascular protection, anti-inflammation, metabolic regulation and neuroprotection, has become an important choice for precise nutritional intervention for sub-health and middle-aged populations and elderly indinduals.
[1] Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)[J]. Am J Cardiol, 2011, 108(5): 682-690.
[2] Miller M, Ryan A, Reed RM, et al. Effect of Icosapent Ethyl on Gynoid Fat and Bone Mineral Health in the Metabolic Syndrome: A Preliminary Report[J]. Clin Ther, 2020, 42(11): 2226-2230.
[3] Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis[J]. Lancet, 2007, 369(9567): 1090-1098.
[4] Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia[J]. N Engl J Med, 2019, 380(1): 11-22.
